Nuclear PI-PLC β1 and myelodysplastic syndromes: From bench to clinics

Current Topics in Microbiology and Immunology

Volumn 362, Issue , 2012, Pages 235-245

  Mongiorgi, Sara ^a   Follo, Matilde Y ^a   Clissa, Cristina ^a   Giardino, Roberto ^b   Fini, Milena ^b   Manzoli, Lucia ^a   Ramazzotti, Giulia ^a   Fiume, Roberta ^a   Finelli, Carlo ^a   Cocco, Lucio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYCLIN D3; DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE PHOSPHODIESTERASE; PHOSPHOINOSITIDE SPECIFIC PHOSPHOLIPASE C BETA1; PHOSPHOINOSITIDE SPECIFIC PHOSPHOLIPASE C BETA3; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 1; STAT5 PROTEIN; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHROMOSOME 20P; DNA METHYLATION; DRUG POTENTIATION; GENE DELETION; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HISTONE ACETYLATION; HUMAN; LOW DRUG DOSE; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION;

EID: 84870031043     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-007-5025-8_11     Document Type: Article

References (50)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199 (Pubitemid 12073508)
2. Braiteh F, Soriano AO, Garcia-Manero G et al (2008) Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 14:6296-6301
3. Cain JA, Xiang Z, O'Neal J et al (2007) Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage. Blood 109:3906-3914 (Pubitemid 46641743)
4. Choudhary C, Brandts C, Schwable J et al (2007) Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood 110:370-374 (Pubitemid 47026856)
5. Cooper AB, Sawai CM, Sicinska E, Powers SE, Sicinski P, Clark MR, Aifantis I (2006) A unique function for cyclin D3 in early B cell development. Nat Immunol 7:489-497
6. Daskalakis M, Nguyen TT, Nguyen C et al (2002) Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 100:2957-2964
7. Faenza I, Bregoli L, Ramazzotti G et al (2008) Nuclear phospholipase Cbeta1 and cellular differentiation. Front Biosci 13:2452-2463 (Pubitemid 351599697)
8. Faenza I, Matteucci A, Manzoli L et al (2000) A role for nuclear phospholipase Cbeta1 in cell cycle control. J Biol Chem 275:30520-30524
9. Faenza I, Ramazzotti G, Bavelloni A et al (2007) Inositide-dependent phospholipase C signaling mimics insulin in skeletal muscle differentiation by affecting specific regions of the cyclin D3 promoter. Endocrinology 148:1108-1117
10. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223-232
11. Fenaux P, Raza A, Mufti GJ et al (2007) A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate-to high-risk myelodysplastic syndrome. Blood 109:4158-4163 (Pubitemid 46743377)
12. Fiume R, Ramazzotti G, Teti G et al (2009) Involvement of nuclear PLCbeta1 in lamin B1 phosphorylation and G2/M cell cycle progression. FASEB J 23:957-966
13. Follo MY, Bosi C, Finelli C et al (2006) Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome. Int J Mol Med 18:267-271
14. Follo MY, Finelli C, Bosi C et al (2008) PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes. Leukemia 22:198-200
15. Follo MY, Finelli C, Clissa C et al (2009a) Phosphoinositide- phospholipase Cbeta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. J Clin Oncol 27:782-790
16. Follo MY, Finelli C, Mongiorgi S et al (2009b) Reduction of phosphoinositide-phospholipase Cbeta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci U S A 106:16811-16816
17. Follo MY, Finelli C, Mongiorgi S et al (2011) Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. Leukemia 25:271-280
18. Follo MY, Mongiorgi S, Bosi C et al (2007) The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. Cancer Res 67:4287-4294 (Pubitemid 46815076)
19. Follo MY, Mongiorgi S, Finelli C et al (2010) Nuclear inositide signaling in myelodysplastic syndromes. J Cell Biochem 109:1065-1071
20. Furukawa Y (2002) Cell cycle control genes and hematopoietic cell differentiation. Leuk Lymphoma 43:225-231 (Pubitemid 34202099)
21. Greenberg P, Cox C, Le Beau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088 (Pubitemid 27132124)
22. Griffiths EA, Gore SD (2008) DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol 45:23-30
23. Jabbour E, Kantarjian HM, Koller C, Taher A (2008) Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer 112:1089-1095 (Pubitemid 351304594)
24. Kaminskas E, Farrell A, Abraham S et al (2005) Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11:3604-3608 (Pubitemid 40685574)
25. Malcovati L, Germing U, Kuendgen A et al (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503-3510 (Pubitemid 47315575)
26. Martelli AM, Fiume R, Faenza I et al (2005) Nuclear phosphoinositide specific phospholipase C (PI-PLC)-beta1: a central intermediary in nuclear lipid-dependent signal transduction. Histol Histopathol 20:1251-1260 (Pubitemid 41489167)
27. Martelli AM, Gilmour RS, Bertagnolo V, Neri LM, Manzoli L, Cocco L (1992) Nuclear localization and signalling activity of phosphoinositidase Cbeta in Swiss 3T3 cells. Nature 358:242-245
28. Mercurio C, Minucci S, Pelicci PG (2010) Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 62:18-34
29. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51 (Pubitemid 43054973)
30. Morgan MA, Reuter CW (2006) Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias. Ann Hematol 85:139-163 (Pubitemid 43174269)
31. Neff T, Armstrong SA (2009) Chromatin maps, histone modifications and leukemia. Leukemia 23:1243-1251
32. Nyakern M, Tazzari PL, Finelli C et al (2006) Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia 20:230-238 (Pubitemid 43148660)
33. O'Carroll SJ, Mitchell MD, Faenza I, Cocco L, Gilmour RS (2009) Nuclear PLCbeta1 is required for 3T3-L1 adipocyte differentiation and regulates expression of the cyclin D3-cdk4 complex. Cell Signal 21:926-935
34. Park S, Chapuis N, Bardet V et al (2008) PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 22:1698-1706
35. Perl AE, Kasner MT, Tsai DE et al (2009) A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 15:6732-6739
36. Peruzzi D, Calabrese G, Faenza I et al (2000) Identification and chromosomal localisation by fluorescence in situ hybridisation of human gene of phosphoinositide-specific phospholipase Cbeta1. Biochim Biophys Acta 1484:175-182 (Pubitemid 30175967)
37. Quintas-Cardama A, Tong W, Kantarjian H et al (2008) A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/ polycythemia vera myelofibrosis. Leukemia 22:965-970 (Pubitemid 351689878)
38. Raj K, John A, Ho A et al (2007) CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 21:1937-1944 (Pubitemid 47299967)
39. Schwaller J, Parganas E, Wang D et al (2000) Stat5 is essential for the myelo-and lymphoproliferative disease induced by TEL/JAK2. Mol Cell 6:693-704
40. Sekeres MA, Maciejewski JP, Giagounidis AA, Wride K, Knight R, Raza A, List AF (2008) Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 26:5943-5949
41. Silverman LR, Mufti GJ (2005) Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Nat Clin Pract Oncol 2(Suppl 1):12-23
42. Srinivasan S, Schiffer CA (2008) Current treatment options and strategies for myelodysplastic syndromes. Expert Opin Pharmacother 9:1667-1678
43. Stresemann C, Lyko F (2008) Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 123:8-13 (Pubitemid 351705186)
44. Suh PG, Park JI, Manzoli L et al (2008) Multiple roles of phosphoinositide-specific phospholipase C isozymes. BMB Rep 41:415-434 (Pubitemid 351914885)
45. Tefferi A, Vardiman JW (2009) Myelodysplastic syndromes. N Engl J Med 361:1872-1885
46. Vardiman JW, Thiele J, Arber DA et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937-951
47. Xiao W, Ando T, Wang HY, Kawakami Y, Kawakami T (2010) Lyn-and PLCbeta3-dependent regulation of SHP-1 phosphorylation controls Stat5 activity and myelomonocytic leukemialike disease. Blood 116:6003-6013
48. Xiao W, Hong H, Kawakami Y et al (2009) Tumor suppression by phospholipase Cbeta3 via SHP-1-mediated dephosphorylation of Stat5. Cancer Cell 16:161-171
49. Xiao W, Hong H, Kawakami Y, Lowell CA, Kawakami T (2008) Regulation of myeloproliferation and M2 macrophage programming in mice by Lyn/Hck, SHIP, and Stat5. J Clin Invest 118:924-934 (Pubitemid 351364600)
50. Ye K (2005) PIKE/nuclear PI 3-kinase signaling in preventing programmed cell death. J Cell Biochem 96:463-472 (Pubitemid 41504645)